Further investigation of a NRF2/COX-2/PGE2 axis may yield justification for combination immunotherapy treatments using COX-2 inhibitors to “sensitize” immune cells and checkpoint blockade to induce anti-cancer responses in patients bearing KEAP1 mutations. This evidence concerns the gene NFE2L2 and cancer.